We are live on ! Find out more

9 hedge funds and large institutions have $384K invested in DNA X in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more capital inflows, than outflows

Capital inflows: $342K | Capital outflows: $194K

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

13% more funds holding

Funds holding: 8 → 9 (+1)

1.82% less ownership

Funds ownership: 8.22% → 6.4% (-1.8%)

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SONM Hedge Fund Activity: Q1 2026 in Review

9 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in DNA X (SONM) for Q1 2026, worth a combined $384K — up 44% from $266K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SONM positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $130K. The largest seller was Potomac Capital Management, exiting entirely with an estimated $151K sold.

  • 9 institutional investors held DNA X (SONM) as of Q1 2026, up from 8 in Q4 2025.
  • Funds reported $384K of DNA X stock for Q1 2026, up 44% quarter-over-quarter.
  • 5 funds opened new DNA X positions in Q1 2026 and 4 closed out, a net change of +1 holder.
  • The largest DNA X buyer in Q1 2026 was UBS Group, an estimated $130K added.
  • The largest DNA X seller in Q1 2026 was Potomac Capital Management, an estimated $151K sold.

Based on aggregated 13F filings for Q1 2026.